FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2886443306> ?p ?o ?g. }

• W2886443306 abstract "Tyrosine kinase inhibitors (TKI) have achieved great success for cancer patients with aberrant target genes such as ROS1, NTRKs and ALK. However, the inevitable emergence of drug resistance limits their long-term clinical benefits. Ropotrectinib (TPX-0005), a brain-tumor penetrable ROS1/TRK/ALK kinase inhibitor, was designed not only to target abnormal activity of ROS1, TRK and ALK but also to overcome drug resistance caused by previous ROS1, NTRK and ALK inhibitors. The unique structure design of roporectinib granted it the unique ability to overcome acquired solvent front mutations in the targeted kinase domain caused by other TKIs. Moreover, ropotrectinib displays inhibitory activity for SRC/FAK/JAK2, rendering its potential to overcome drug resistance caused by “by-passing” mechanisms such as EMT. Ropotrectinib is a superb ROS1 inhibitor. The ALK/ROS1/MET inhibitor crizotinib has been approved by FDA to treat NSCLC patients harboring a rearranged ROS1 fusion gene. Acquired secondary mutations in ROS1 kinase domain is a common drug resistance mechanism in 50-60% patients progressed on crizotinib treatment, with solvent front mutations most frequently observed. Compared to other ROS1 inhibitors, such as lorlatinib, ceritinib, brigatinib and entrectinib, ropotrectinb demonstrated most potent activity against WT and mutant ROS1, especially solvent front mutations such as G2032R in cellular assays and potently inhibited xenograft tumors. Ropotrectinib is the most potent TRK inhibitors in clinic, with IC 50 s G595R fusion gene, ropotrectinib (IC 50 50 = 7nM), a second generation of TRK inhibitor in clinic. Ropotrectinib is also a ALK inhibitor with CNS activity, inhibiting growth and viability of ALK + cells, inducing tumor regression in a ALK + PDX tumor model and significantly improving overall survival of mice bearing CNS ALK + H2228 tumors. In particular, compared to previous generations of ALK inhibitors (e.g. crizontinib, ceritinib, alectinib, and brigatinib), it exhibited superb activity in those acquired mutations, especially the G1202R solvent front mutation and double mutations containing L1198F. Roporectinib dose-dependently down-regulated EGFR, CD44 and vimentin expression levels via SRC/FAK inhibition, suggesting a potential to prevent EMT. In summary, ropotrectinib exerts unique pharmacological properties for clinical applications in patients harboring aberrant ROS1/TRK/ALK. A Phase 1/2 clinical trial of TPX-0005 is actively pursued (NCT03093116). Citation Format: Wei Deng, Dayong Zhai, John Huang, Evan Rogers, Jeffrey Whitten, John Lim, Yishan Li, Jean Cui. Ropotrectinib is a novel polypharmacology kinase inhibitor against WT and mutant ROS1, TRK and ALK [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4796." @default.
• W2886443306 created "2018-08-22" @default.
• W2886443306 creator A5021418856 @default.
• W2886443306 creator A5031987801 @default.
• W2886443306 creator A5032838816 @default.
• W2886443306 creator A5046083817 @default.
• W2886443306 creator A5055510705 @default.
• W2886443306 creator A5074829279 @default.
• W2886443306 creator A5075969720 @default.
• W2886443306 creator A5076486692 @default.
• W2886443306 date "2018-07-01" @default.
• W2886443306 modified "2023-09-27" @default.
• W2886443306 title "Abstract 4796: Ropotrectinib is a novel polypharmacology kinase inhibitor against WT and mutant ROS1, TRK and ALK" @default.
• W2886443306 doi "https://doi.org/10.1158/1538-7445.am2018-4796" @default.
• W2886443306 hasPublicationYear "2018" @default.
• W2886443306 type Work @default.
• W2886443306 sameAs 2886443306 @default.
• W2886443306 citedByCount "0" @default.
• W2886443306 crossrefType "proceedings-article" @default.
• W2886443306 hasAuthorship W2886443306A5021418856 @default.
• W2886443306 hasAuthorship W2886443306A5031987801 @default.
• W2886443306 hasAuthorship W2886443306A5032838816 @default.
• W2886443306 hasAuthorship W2886443306A5046083817 @default.
• W2886443306 hasAuthorship W2886443306A5055510705 @default.
• W2886443306 hasAuthorship W2886443306A5074829279 @default.
• W2886443306 hasAuthorship W2886443306A5075969720 @default.
• W2886443306 hasAuthorship W2886443306A5076486692 @default.
• W2886443306 hasConcept C117643217 @default.
• W2886443306 hasConcept C121608353 @default.
• W2886443306 hasConcept C126322002 @default.
• W2886443306 hasConcept C134139212 @default.
• W2886443306 hasConcept C170493617 @default.
• W2886443306 hasConcept C184235292 @default.
• W2886443306 hasConcept C2775999482 @default.
• W2886443306 hasConcept C2776232967 @default.
• W2886443306 hasConcept C2776256026 @default.
• W2886443306 hasConcept C2778347629 @default.
• W2886443306 hasConcept C2779422266 @default.
• W2886443306 hasConcept C2779750558 @default.
• W2886443306 hasConcept C2781182431 @default.
• W2886443306 hasConcept C42362537 @default.
• W2886443306 hasConcept C502942594 @default.
• W2886443306 hasConcept C55493867 @default.
• W2886443306 hasConcept C62478195 @default.
• W2886443306 hasConcept C71924100 @default.
• W2886443306 hasConcept C86803240 @default.
• W2886443306 hasConcept C92020748 @default.
• W2886443306 hasConcept C98274493 @default.
• W2886443306 hasConceptScore W2886443306C117643217 @default.
• W2886443306 hasConceptScore W2886443306C121608353 @default.
• W2886443306 hasConceptScore W2886443306C126322002 @default.
• W2886443306 hasConceptScore W2886443306C134139212 @default.
• W2886443306 hasConceptScore W2886443306C170493617 @default.
• W2886443306 hasConceptScore W2886443306C184235292 @default.
• W2886443306 hasConceptScore W2886443306C2775999482 @default.
• W2886443306 hasConceptScore W2886443306C2776232967 @default.
• W2886443306 hasConceptScore W2886443306C2776256026 @default.
• W2886443306 hasConceptScore W2886443306C2778347629 @default.
• W2886443306 hasConceptScore W2886443306C2779422266 @default.
• W2886443306 hasConceptScore W2886443306C2779750558 @default.
• W2886443306 hasConceptScore W2886443306C2781182431 @default.
• W2886443306 hasConceptScore W2886443306C42362537 @default.
• W2886443306 hasConceptScore W2886443306C502942594 @default.
• W2886443306 hasConceptScore W2886443306C55493867 @default.
• W2886443306 hasConceptScore W2886443306C62478195 @default.
• W2886443306 hasConceptScore W2886443306C71924100 @default.
• W2886443306 hasConceptScore W2886443306C86803240 @default.
• W2886443306 hasConceptScore W2886443306C92020748 @default.
• W2886443306 hasConceptScore W2886443306C98274493 @default.
• W2886443306 hasLocation W28864433061 @default.
• W2886443306 hasOpenAccess W2886443306 @default.
• W2886443306 hasPrimaryLocation W28864433061 @default.
• W2886443306 hasRelatedWork W1806166951 @default.
• W2886443306 hasRelatedWork W2168959119 @default.
• W2886443306 hasRelatedWork W2529194187 @default.
• W2886443306 hasRelatedWork W2565081035 @default.
• W2886443306 hasRelatedWork W2739616532 @default.
• W2886443306 hasRelatedWork W2758151171 @default.
• W2886443306 hasRelatedWork W2789632821 @default.
• W2886443306 hasRelatedWork W2885292615 @default.
• W2886443306 hasRelatedWork W2886443306 @default.
• W2886443306 hasRelatedWork W4200117073 @default.
• W2886443306 isParatext "false" @default.
• W2886443306 isRetracted "false" @default.
• W2886443306 magId "2886443306" @default.
• W2886443306 workType "article" @default.